ProCE Banner Activity

CE / CME

Exploring New Diagnostic and Therapeutic Possibilities in Chronic Spontaneous Urticaria

Video

Chronic spontaneous urticaria (CSU) leads to a significant impairment on a patient’s quality of life. Additionally, many patients with CSU do not achieve complete symptom control and are thus considered to have refractory disease. In this webcast, Jonathan A. Bernstein, MD provides steps for the appropriate diagnosis of CSU, discusses guideline-directed treatment, and gives considerations for emerging treatment options for patients with CSU.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: December 01, 2022

Expiration: November 30, 2023

No longer available for credit.

Share

Faculty

Jonathan A. Bernstein

Jonathan A. Bernstein, MD

Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Rheumatology, Allergy and Immunology
Partner Bernstein Allergy Group and Bernstein Clinical Research Center
Cincinnati, Ohio

Kristine Kucera

Kristine Kucera, PA-C, MPAS, DHS

Physician Assistant
Bare Dermatology
Dallas, Texas
Adjunct Assistant Professor
UNT Health Science Center, PA Program
Ft. Worth, Texas

Provided by

ProCE Banner
ProCE Banner

Supporters

Supported by educational grants from Novartis Pharmaceuticals Corporation and Sanofi and Regeneron Pharmaceuticals.

Novartis Pharmaceuticals Corporation

Sanofi and Regeneron Pharmaceuticals

Target Audience

Dermatologists and NPs, PAs, nurses, and physicians who practice in dermatology

Disclosure

All faculty and planners participating in continuing education activities sponsored by Clinical Care Options, LLC (CCO) and Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to CCO and PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Jonathan A. Bernstein, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Novartis, Sanofi/Regeneron; researcher: Allakos, Amgen, AstraZeneca, Celldex, Genentech, Sanofi/Regeneron, TLL.

Victoria Garcia-Albea, NP, DCNP: consultant/advisor/speaker: Sanofi-Genzyme.

Kristine Kucera, PA-C, MPAS, DHSc: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

The planners and content peer reviewers from Clinical Care Options, LLC, Partners for Advancing Clinical Education, and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Victoria Garcia-Albea, NP, DCNP, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

1.       View the content in its entirety

2.       Relate the content material to the learning objectives 

3.       Complete evaluation form 

The estimated time to complete this activity is 0.50 hours.

Release date: December, 1, 2022
Expiration date: November 30, 2023

Format

This activity has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Clinical Care Options, LLC, Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.

Accreditation

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

 

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit
NP course advisor: Victoria Garcia-Albea, NP, DCNP, Lahey Hospital and Medical Center, Burlington, Massachusetts

 

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credit. Approval is valid until November 30, 2023. PAs should only claim credit commensurate with the extent of their participation.

 

 

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.